Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

J&J's Simponi Helps Colitis Patients In Clinical Trial

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/21/2012 | 08:45pm CET
   By Peter Loftus 
   Of  
 

Johnson & Johnson (>> Johnson & Johnson) said its drug Simponi improved symptoms in a majority of patients with an inflammatory-bowel disease in a new clinical trial.

The results, released at a medical conference Monday, could support expansion of the approved uses of Simponi to include treating the bowel condition, known as ulcerative colitis, which J&J estimates affects about 700,000 people in the U.S.

Simponi, which was introduced in 2009, is currently approved to treat signs and symptoms of moderate to severe rheumatoid arthritis, active psoriatic arthritis and active ankylosing spondylitis.

Simponi is known as an anti-tumor necrosis factor, or anti-TNF, a category that also includes J&J's older drug, Remicade, which is already approved to treat ulcerative colitis. Simponi can be self-administered by patients as an injection, while Remicade requires intravenous infusion by a health-care provider.

J&J recorded $410 million in Simponi sales for 2011; Merck & Co. (MRK), which markets the drug in certain countries outside the U.S., recorded $264 million in Simponi sales for 2011.

J&J tested Simponi in a late-stage clinical trial of more than 770 patients with moderately to severely active ulcerative colitis who had failed to respond to or tolerate certain other treatments.

Some patients received Simponi--at two different dose levels--and some received a placebo, and researchers tracked how many experienced a clinical response at six weeks after the start of treatment. Clinical response included improvements in various symptoms of ulcerative colitis such as diarrhea.

According to J&J, 51.8% and 55% of patients in the two Simponi groups, respectively, achieved a clinical response at week 6, versus 29.7% of placebo patients. The results were presented Monday at the Digestive Disease Week medical meeting in San Diego.

In a secondary measure in the trial, roughly 18.7% and 17.8% of patients in the Simponi groups had clinical remission, versus 6.3% in placebo patients.

The rates of adverse events were comparable among the Simponi and placebo groups, and J&J said the safety of Simponi in the colitis study was consistent with the drug's safety profile in the diseases for which it's already approved.

As a class of drugs, Simponi and other anti-TNFs are associated with increased risk of infections and certain forms of cancer such as lymphoma.

The data suggest Simponi could be a new treatment option for ulcerative colitis patients who don't respond to other drugs, or who prefer the convenience of a subcutaneous injection, said William Sandborn, chief of the division of gastroenterology at the University of California, San Diego, and lead investigator of the J&J-funded study.

J&J also has studied Simponi over a longer treatment duration in colitis patients, and results are expected later this year.

J&J plans to apply for U.S. and European regulatory approval of Simponi as a treatment for ulcerative colitis this year, said J&J spokesman Brian Kenney.

Abbott Laboratories (>> Abbott Laboratories) also has applied for regulatory approval of its anti-inflammatory drug, Humira, as a treatment for ulcerative colitis. European regulators have approved the new indication.

Last year, the FDA declined to approve J&J's requests to market Simponi's ability to inhibit progression of structural damage in both rheumatoid arthritis and psoriatic arthritis.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

Stocks mentioned in the article : Johnson & Johnson, Abbott Laboratories
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
02:04p J&J latest to suspend ads from YouTube over offensive videos
03/22 JOHNSON & JOHNSON : Tech firm seeks $3.3 in tax credits; plans move to R.I.
03/22 JOHNSON & JOHNSON : Wants to Tap Innovators Worldwide to Help Create the Healthi..
03/21 JOHNSON & JOHNSON : Ministry of Health launches Diabetes Early Detection Program..
03/21 JOHNSON & JOHNSON : to Host Investor Conference Call on First-Quarter Results
03/21 JOHNSON & JOHNSON : Global Dental Anesthesia Market Key Players Astra Zeneca, Se..
03/18 JOHNSON & JOHNSON : New Phase 3 Study Finds XARELTO® to Be Superior to Aspirin f..
03/18 JOHNSON & JOHNSON : New Phase 3 Study Finds XARELTO to Be Superior to Aspirin fo..
03/17 JOHNSON & JOHNSON : University of Leicester - Leicester Precision Medicine Insti..
03/17 JOHNSON & JOHNSON : opens regional offices in Ghana and Kenya
More news
Sector news : Pharmaceuticals - NEC
11:53a TEVA PHARMACEUTICAL INDUSTRIES : Pharm says media reports of up to 6,000 layoffs..
03/22 MYLAN : recalls 81,000 EpiPens outside U.S. after reports of failure
03/21DJSANOFI'S PRESCRIPTION FOR GROWTH : Drug Sales in the Middle Kingdom
03/20 FTSE rises to record close after Article 50 trigger date set
03/17DJPFIZER : Files 8K - Other Events
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
03/22 CROWN CASTLE INTERNATIONAL : A Specialty Utility In REIT's Clothing
03/22 Wells Fargo sees significant upside in Xarelto sales if use expanded to CV ri..
03/22 WORD ON WALL STREET : Pharma Segment Key To Johnson & Johnson's 2017 Performance
03/22 JOHNSON & JOHNSON : Great Business With A Great Future - A Great Time To Buy?
03/22 5 Dividend Stocks Expected To Increase Distributions In 2017
Advertisement
Financials ($)
Sales 2017 74 632 M
EBIT 2017 23 011 M
Net income 2017 17 928 M
Finance 2017 21 362 M
Yield 2017 2,65%
P/E ratio 2017 19,13
P/E ratio 2018 17,85
EV / Sales 2017 4,30x
EV / Sales 2018 4,04x
Capitalization 342 277 M
More Financials
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 126 $
Spread / Average Target 0,03%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON9.59%342 277
ROCHE HOLDING LTD.7.52%217 164
PFIZER INC.6.13%205 273
NOVARTIS AG0.47%194 072
MERCK & CO., INC.7.86%174 344
SANOFI7.63%115 490
More Results